Archer-Daniels-Midland Company (ADM) reports lower Q4 revenue and earnings

Watch Icon
AlphaStreet

Archer-Daniels-Midland Company (NYSE: ADM), a leading provider of human and animal nutrition solutions, on Tuesday reported earnings for the fourth quarter of 2023.

Fourth-quarter revenues decreased to $22.98 billion from $25.94 billion in the same period of last yearThe company reported net income of $565 million or $1.06 per share for the December quarter, vs. $1.02 billion or $1.84 per share in the prior-year periodOn an adjusted basis, Q4 earnings came in at $1.36 per share, compared to $1.93 per share a year earlier Segment operating profit was $1.24 billion, including one-time charges of $171 million, or approximately $0.30 per shareFor fiscal 2024, the company expects adjusted earnings per share in the range of $5.25 to $6.25 per share, down 18% at the midpoint compared to 2023The board authorized the repurchase of an additional $2 billion of the company’s shares under the existing 200 million share repurchase program

The post Archer-Daniels-Midland Company (ADM) reports lower Q4 revenue and earnings first appeared on AlphaStreet.

 

John Gachora: NCBA CEO on why fundamentals are not explaining shilling performance | Investorempires.com

Read More | Boss Talk John Gachora: NCBA CEO on why fundamentals are not explaining shilling performance Friday March 29 2024 NCBA CEO, John Gachora. ILLUSTRATION | JOSEPH BARASA | NMG NCBA Group managing director and Kenya Bankers Association chairman John Gachora reflects on his bank’s 2023 full-year performance and the industry’s standing that featured strong […]

$2K challenge update | Raging Bull

Read More |    TGIF! I’ll be teaching Saturday, Sunday and Monday on Facebook at 10 AM ET. What a week! The $2,000 balance challenge started the week at $15,744 and finished up +$2,744 to $18,488. Creating consistency like this requires that you completely accept that trading isn’t about hoping, wondering, or gathering evidence one […]

Aprea Therapeutics secures up to $34 million in financing By Investing.com | Investorempires.com

Read More | © Reuters. DOYLESTOWN, Pa. – Aprea Therapeutics, Inc. (NASDAQ:), a biopharmaceutical company specializing in precision oncology, announced today that it has entered into a securities purchase agreement with healthcare-focused institutional investors and insiders to raise up to $34 million. The financing includes an upfront amount of $16 million with the potential for […]